<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02147834</url>
  </required_header>
  <id_info>
    <org_study_id>201400100</org_study_id>
    <nct_id>NCT02147834</nct_id>
  </id_info>
  <brief_title>Effectiveness of Ranolazine on Reducing Chest Pain in Patients With Blockage But no Stents</brief_title>
  <acronym>IMWELL3</acronym>
  <official_title>Effect of Ranolazine After Deferral of Percutaneous Coronary Intervention by Fractional Flow Reserve (IMWELL3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>North Florida Foundation for Research and Education</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Florida</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>North Florida Foundation for Research and Education</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if ranolazine improves angina symptoms at 4 months compared with placebo among&#xD;
      patients who are deferred for receiving a Percutaneous Coronary Intervention (PCI) based on&#xD;
      the Fractional Flow Reserve (FFR) measurement.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, double-blind, placebo-controlled, randomized, single-center (North&#xD;
      Florida- South Georgia VA Medical Center) study. The study objective is to determine if&#xD;
      ranolazine improves angina symptoms at 4 months compared with placebo among patients who are&#xD;
      deferred from having a PCI based on the FFR measurement.&#xD;
&#xD;
      Baseline Procedure:&#xD;
&#xD;
      Assessments performed exclusively to determine eligibility for this study would be done only&#xD;
      after obtaining informed consent. Assessments performed for clinical indications (not&#xD;
      exclusively to determine study eligibility) may be used for baseline values even if the&#xD;
      studies were done before informed consent was obtained. The assessment will include:&#xD;
&#xD;
        -  Informed Consent&#xD;
&#xD;
        -  Review subject eligibility criteria&#xD;
&#xD;
        -  FFR value calculated at the time of cardiac catheterization&#xD;
&#xD;
        -  Review previous and concomitant medications&#xD;
&#xD;
        -  Frequency of symptoms and quality of life prior to study according to Seattle Angina&#xD;
           Questionnaire (SAQ)&#xD;
&#xD;
      Screening Visit:&#xD;
&#xD;
      The assessments to determine eligibility are:&#xD;
&#xD;
        -  Review of eligibility criteria&#xD;
&#xD;
        -  Review of cardiac catheterization and FFR&#xD;
&#xD;
        -  Review of medications taken in the past 30 days&#xD;
&#xD;
      Subjects that meet eligibility criteria will be randomized to receive either the active drug,&#xD;
      Ranolazine or a matching placebo (non-active drug). Staff and subjects will not know if the&#xD;
      subject will be receiving the active drug or the placebo.&#xD;
&#xD;
      Drug schedule will be as follows:&#xD;
&#xD;
        -  1st dose of one tablet (500mg) will begin the evening of Day 1&#xD;
&#xD;
        -  On Days 2-7, one tablet (500mg) two times a day (12-hours apart).&#xD;
&#xD;
        -  On Day 8, increase dose of study drug to two tablets (1000mg) twice a day; once in the&#xD;
           morning and once in the evening, 12 hours apart. This dose will continue for the&#xD;
           duration of the study. The study drug can be taken with or without food.&#xD;
&#xD;
      Telephone Follow-up:&#xD;
&#xD;
      One week phone calls will be made to determine well being, adverse events, answer questions&#xD;
      and remind subjects to increase the study medication dose.&#xD;
&#xD;
      Two month phone calls will be made to determine well being and adverse events.&#xD;
&#xD;
      Month 4 Follow-up:&#xD;
&#xD;
        -  Frequency of symptoms and quality of life according to Seattle Angina Questionnaire&#xD;
           (SAQ)&#xD;
&#xD;
        -  Assessment of well-being&#xD;
&#xD;
        -  Any hospitalizations or the need for revascularization&#xD;
&#xD;
      Subjects will take the study medication for 16 weeks and will receive a phone call from the&#xD;
      study coordinator 30 days after last dose of study medication.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    due to futility&#xD;
  </why_stopped>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Seattle Angina Questionnaire Score Change From Baseline to Month 4</measure>
    <time_frame>Change in baseline to month 4</time_frame>
    <description>The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subjective Well Being</measure>
    <time_frame>Compare from baseline to month 4</time_frame>
    <description>overall feeling of well being determined from rating of excellent, good, fair or poor at baseline compared to same at month 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemia Driven Revascularization or Hospitalization</measure>
    <time_frame>4 month</time_frame>
    <description>frequency of the number of reported adverse events for ischemia driven revascularization or hospitalization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Angina</condition>
  <arm_group>
    <arm_group_label>Ranolazine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Sugar pill that looks like the drug ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ranolazine</intervention_name>
    <description>Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
    <arm_group_label>Ranolazine</arm_group_label>
    <other_name>Ranexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>sugar pill manufactured to mimic ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stable patients &gt;= 18 years of age referred for cardiac catheterization for evaluation&#xD;
             of cardiac symptoms ( angina, fatigue, or shortness of breath)&#xD;
&#xD;
          -  At least 1 indeterminate stenosis (20-80%), fractional flow reserve (FFR) &gt;=0.8 and&#xD;
             PCI deferred&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Coronary revascularization (percutaneous coronary intervention or coronary artery&#xD;
             bypass grafting) during the index procedure or anticipated within the next month&#xD;
&#xD;
          -  acute coronary syndrome or cardiogenic shock&#xD;
&#xD;
          -  use of strong inhibitors of CTP3A (i.e. ketoconazole, itraconazole,&#xD;
             clarithromycin,nefazodone, nelfinavir, ritonavir, indinavir and saquinavir)&#xD;
&#xD;
          -  use of inducers of CYP3A (i.e. rifampin, rifabutin, rifapentine, phenobarbital,&#xD;
             phenytoin, carbamazepine, and St. John's wort)&#xD;
&#xD;
          -  liver cirrhosis&#xD;
&#xD;
          -  sever renal insufficience (i.e. creatinine clearance &lt; 30mL/min/1.73 m2)&#xD;
&#xD;
          -  QTc &gt; 500 milliseconds&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony A Bavry, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>North Florida/South Georgia Veterans Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Florida/South Georgia Veterans Health System</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>May 22, 2014</study_first_submitted>
  <study_first_submitted_qc>May 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2014</study_first_posted>
  <results_first_submitted>May 22, 2019</results_first_submitted>
  <results_first_submitted_qc>May 22, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">June 11, 2019</results_first_posted>
  <last_update_submitted>May 22, 2019</last_update_submitted>
  <last_update_submitted_qc>May 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>deferred percutaneous coronary intervention</keyword>
  <keyword>fractional flow reserve</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranolazine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>5 subjects enrolled. First subjected enrolled 8/7/2015 and last enrolled on 11/19/2015. enrollment discontinued early by investigator due to futility.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ranolazine</title>
          <description>Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Ranolazine: Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
        </group>
        <group group_id="P2">
          <title>Sugar Pill</title>
          <description>Sugar pill that looks like the drug ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Sugar pill: sugar pill manufactured to mimic ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ranolazine</title>
          <description>Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Ranolazine: Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
        </group>
        <group group_id="B2">
          <title>Sugar Pill</title>
          <description>Sugar pill that looks like the drug ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Sugar pill: sugar pill manufactured to mimic ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Seattle Angina Questionnaire Score Change From Baseline to Month 4</title>
        <description>The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception).</description>
        <time_frame>Change in baseline to month 4</time_frame>
        <population>The investigator ended this project early due to futility. Do data was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Ranolazine: Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Sugar pill that looks like the drug ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Sugar pill: sugar pill manufactured to mimic ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Seattle Angina Questionnaire Score Change From Baseline to Month 4</title>
          <description>The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception).</description>
          <population>The investigator ended this project early due to futility. Do data was analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subjective Well Being</title>
        <description>overall feeling of well being determined from rating of excellent, good, fair or poor at baseline compared to same at month 4</description>
        <time_frame>Compare from baseline to month 4</time_frame>
        <population>The investigator ended this study early due to futility. no data was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Ranolazine: Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Sugar pill that looks like the drug ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Sugar pill: sugar pill manufactured to mimic ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Subjective Well Being</title>
          <description>overall feeling of well being determined from rating of excellent, good, fair or poor at baseline compared to same at month 4</description>
          <population>The investigator ended this study early due to futility. no data was analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ischemia Driven Revascularization or Hospitalization</title>
        <description>frequency of the number of reported adverse events for ischemia driven revascularization or hospitalization</description>
        <time_frame>4 month</time_frame>
        <population>The investigator ended this study early due to futility. No data was analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Ranolazine</title>
            <description>Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Ranolazine: Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
          </group>
          <group group_id="O2">
            <title>Sugar Pill</title>
            <description>Sugar pill that looks like the drug ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Sugar pill: sugar pill manufactured to mimic ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Ischemia Driven Revascularization or Hospitalization</title>
          <description>frequency of the number of reported adverse events for ischemia driven revascularization or hospitalization</description>
          <population>The investigator ended this study early due to futility. No data was analyzed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>baseline to 4 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ranolazine</title>
          <description>Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Ranolazine: Ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
        </group>
        <group group_id="E2">
          <title>Sugar Pill</title>
          <description>Sugar pill that looks like the drug ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks&#xD;
Sugar pill: sugar pill manufactured to mimic ranolazine 500mg tablet&#xD;
500mg tablet two times per day for 7 days then,&#xD;
500mg tablet (1000mg) two times per day for 15 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anthony A Bavry, M.D.</name_or_title>
      <organization>North Florida South Georigai Veteran Health System</organization>
      <phone>352-548-6000 ext 104726</phone>
      <email>anthony.bavry@va.gov</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

